Multiple Targets for Novel Therapy of FSGS Associated with Circulating Permeability Factor
المؤلفون المشاركون
Sharma, Mukut
Sharma, Ram
Savin, Virginia J.
Zhou, Jianping
McCarthy, Ellen T.
Genochi, David
Ilahe, Amna
Budhiraja, Pooja
Gupta, Aditi
Srivastava, T.
المصدر
العدد
المجلد 2017، العدد 2017 (31 ديسمبر/كانون الأول 2017)، ص ص. 1-14، 14ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2017-08-10
دولة النشر
مصر
عدد الصفحات
14
التخصصات الرئيسية
الملخص EN
A plasma component is responsible for altered glomerular permeability in patients with focal segmental glomerulosclerosis.
Evidence includes recurrence after renal transplantation, remission after plasmapheresis, proteinuria in infants of affected mothers, transfer of proteinuria to experimental animals, and impaired glomerular permeability after exposure to patient plasma.
Therapy may include decreasing synthesis of the injurious agent, removing or blocking its interaction with cells, or blocking signaling or enhancing cell defenses to restore the permeability barrier and prevent progression.
Agents that may prevent the synthesis of the permeability factor include cytotoxic agents or aggressive chemotherapy.
Extracorporeal therapies include plasmapheresis, immunoadsorption with protein A or anti-immunoglobulin, or lipopheresis.
Oral or intravenous galactose also decreases Palb activity.
Studies of glomeruli have shown that several strategies prevent the action of FSGS sera.
These include blocking receptor-ligand interactions, modulating cell reactions using indomethacin or eicosanoids 20-HETE or 8,9-EET, and enhancing cytoskeleton and protein interactions using calcineurin inhibitors, glucocorticoids, or rituximab.
We have identified cardiotrophin-like cytokine factor 1 (CLCF-1) as a candidate for the permeability factor.
Therapies specific to CLCF-1 include potential use of cytokine receptor-like factor (CRLF-1) and inhibition of Janus kinase 2.
Combined therapy using multiple modalities offers therapy to reverse proteinuria and prevent scarring.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Savin, Virginia J.& Sharma, Mukut& Zhou, Jianping& Genochi, David& Sharma, Ram& Srivastava, T.…[et al.]. 2017. Multiple Targets for Novel Therapy of FSGS Associated with Circulating Permeability Factor. BioMed Research International،Vol. 2017, no. 2017, pp.1-14.
https://search.emarefa.net/detail/BIM-1137995
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Savin, Virginia J.…[et al.]. Multiple Targets for Novel Therapy of FSGS Associated with Circulating Permeability Factor. BioMed Research International No. 2017 (2017), pp.1-14.
https://search.emarefa.net/detail/BIM-1137995
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Savin, Virginia J.& Sharma, Mukut& Zhou, Jianping& Genochi, David& Sharma, Ram& Srivastava, T.…[et al.]. Multiple Targets for Novel Therapy of FSGS Associated with Circulating Permeability Factor. BioMed Research International. 2017. Vol. 2017, no. 2017, pp.1-14.
https://search.emarefa.net/detail/BIM-1137995
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1137995
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر